Skip to main content
×
×
Home

Shifting institutional roles in biomedical innovation in a learning healthcare system

  • REBECCA S. EISENBERG (a1)
Abstract

The use of information technology in healthcare has accelerated progress toward the long-term goal of a learning healthcare system, in which data from prior clinical experience provides an ever-expanding resource to guide continuous improvements in health care. Although still in its early stages, the use of data from clinical experience to supplement data from premarket testing is changing the roles of Food and Drug Administration (FDA) and public and private health insurers in healthcare innovation and technology assessment. It could change who decides what research questions to pursue, whose evidentiary standards decide what counts as actionable knowledge, and who pays the costs of research. The shape and direction of resulting changes will depend on which actors and institutions decide to step forward and claim a larger role in healthcare innovation in response to technological and regulatory change.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Shifting institutional roles in biomedical innovation in a learning healthcare system
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Shifting institutional roles in biomedical innovation in a learning healthcare system
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Shifting institutional roles in biomedical innovation in a learning healthcare system
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
References
Hide All
21st Century Cures Act (2016), Pub. L. No. 114–255 § 3022, codified at 21 US Code § 355g.
Patient Protection and Affordable Care Act (2010), Pub. L. No. 111–48, 124 Stat. 119.
Food and Drug Administration Amendments Act (2007), Pub. L. No. 110–85, 121 Stat. 823.
Medicare Prescription Drug, Improvement, and Modernization Act (2003) Pub. L. No. 108–73, 117 Stat. 2066.
Medical Device Amendments (1976), Pub. L. No. 94–295, 90 Stat. 539.
Argyris, C. and Schön, D. (1996), Organizational Learning II: Theory, Method and Practice, Reading, MA: Addison-Wesley.
Arrow, K. J. (1963), ‘Uncertainty and the Welfare Economics of Medical Care’, American Economic Review, 53 (5): 941973.
Baumann, J. (2012), ‘The “Déjà vu Effect:” Evaluation of United States Medical Device Legislation, Regulation, and the Food and Drug Administration's Contentious 510(k) Program’, Food and Drug Law Journal, 67 (3): 337361.
Beckmann, J. S. and Lew, D. (2016), ‘Reconciling evidence-based medicine and precision in the era of big data: challenges and opportunities’, Genome Medicine, 8: 134. doi 10.1186/s13073-016-1388-7.
Biller-Adorno, N., Lenk, C. and Leititis, J. (2004), ‘Ethics, EBM and hospital management’, Journal of Medical Ethics, 30 (2): 136140.
Black, L. (2007), ‘Experimental Breast Cancer Treatments and Health Insurance Coverage’, Virtual Mentor, 9 (1): 34–7, available at http://journalofethics.ama-assn.org/2007/01/hlaw1-0701.html (accessed 5 March 2018).
Blue Cross Blue Shield Association (2016) ‘Blue Cross Blue Shield Association Launches Evidence Street Website to Streamline Evaluations of Medical Devices, Diagnostics and Pharmaceuticals’, available at https://www.bcbs.com/news/press-releases/blue-cross-blue-shield-association-launches-evidence-street-website-streamline (accessed 5 March 2018).
Bothwell, L. E., Greene, J. A., Podolsky, S. H. and Jones, D. S. (2016), ‘Assessing the Gold Standard – Lessons from the History of RCTs’, New England Journal of Medicine, 374 (22): 21752181.
Brennan, N., Oelschlaeger, A., Cox, C. and Tavenner, M. (2014), ‘Leveraging the Big-Data Revolution: CMS Is Expanding Capabilities to Spur Health System Transformation’, Health Affairs, 33 (7): 11951202.
Carpenter, D. (2010), Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA, Princeton, NJ: Princeton University Press, pp. 118227.
Centers for Medicare and Medicaid Services (2013), ‘Medicare Program; Revised Process for Making National Coverage Determinations’, Federal Register, 78 (152): 48,164169 (CMS 2013 NCD Process).
Centers for Medicare and Medicaid Services (2014) ‘Guidance for the Public, Industry, and CMS Staff: Coverage with Evidence Development’ (CMS 2014 CED Guidance), 20 November 2014, available at https://www.cms.gov/medicare-coverage-database/details/medicare-coverage-document-details.aspx?MCDId=27 (accessed 5 March 2018).
Centers for Medicare and Medicaid Services, Medicare Prescription Drug Manual, ch. 6, § 30.2.5, revised January 2016, available at https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf (accessed 5 March 2018).
Chambers, J. D., Chenoweth, M., Thorat, T. and Neumann, P. J. (2015), ‘Private Payers Disagree With Medicare Over Medical Device Coverage About Half The Time’, Health Affairs, 34 (8): 13761382.
Clinton, W. J. (2000), ‘Memorandum on Increasing Participation of Medicare Beneficiaries in Clinical Trials’, in Public Papers of the Presidents of the United States, William J. Clinton 2000–2001, Book 1, January 1–June 26, 2000, at 1107–9, Washington DC: National Archives and Records Administration, Office of the Federal Register.
Cohen, J. P. and Felix, A. E. (2014), ‘Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement’, Journal of Personalized Medicine, 4 (2): 163175. doi:10.3390/jpm4020163.
Collins, F. S. and Varmus, H. (2015), ‘A New Initiative on Precision Medicine’, New England Journal of Medicine, 372 (9): 793795.
Consoli, D. and Mina, A. (2009), ‘An Evolutionary Perspective on Health Innovation Systems’, Journal of Evolutionary Economics, 19 (2): 297319.
Danzon, P. M. and Nicholson, S. (eds) (2012), The Oxford Handbook of The Economics of the Biopharmaceutical Industry, Oxford: Oxford University Press.
Deverka, P. A. and Dreyfus, J. C. (2014), ‘Clinical Integration of Next Generation Sequencing: Coverage and Reimbursement Challenges’, Journal of Law, Medicine & Ethics, 42 (s1): 2241.
Eddy, D. M. (2005), ‘Evidence-Based Medicine: A Unified Approach’, Health Affairs, 24 (1): 917.
Eisenberg, R. S. (2007), ‘The Role of the FDA in Innovation Policy’, Michigan Telecommunications & Technology Law Review, 13 (2): 345388.
Eisenberg, R. S. (2011), ‘Data Secrecy in the Age of Regulatory Exclusivity’, in Dreyfuss, R. C. and Strandburg, K. J. (eds), The Law and Theory of Trade Secrecy, Northampton, MA: Edward Elgar, pp. 467491.
Eisenberg, R. S. and Price, W. N. II (2017), ‘Promoting Healthcare Innovation on the Demand Side’, Journal of Law Biosciences, 4 (1): 349. doi: 10.1093/jlb/lsw062, at 16–27.
Evans, B. J. (2010), ‘Seven Pillars of a New Evidentiary Paradigm: The Food, Drug, and Cosmetic Act Enters the Genomic Era’, Notre Dame Law Review, 85 (2): 419524.
Evans, B. J. (2012), ‘The Ethics of Postmarketing Observational Studies of Drug Safety under Section 505 (o)(3) of the Food, Drug, and Cosmetic Act’, American Journal of Law & Medicine, 38 (4): 577606.
Every-Palmer, S. and Howick, J. (2014), ‘How Evidence-Based Medicine is Failing Due to Biased Trials and Selective Publication’, Journal of Evaluation in Clinical Practice, 20 (6): 908914.
Evidence Based Medicine Renaissance Group (2014) ‘Evidence Based Medicine: A Movement in Crisis?British Medical Journal, 348: g3725, available at www.bmj.com/content/348/bmj.g3725 (accessed 5 March 2018).
Evidence-Based Medicine Working Group (1992), ‘Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine’, Journal of the American Medical Association, 268 (17): 24202425.
FDA (2014a), ‘ In Vitro Companion Diagnostic Devices Guidance for Industry and Food and Drug Administration Staff’, Food and Drug Administration.
FDA (2014b), ‘Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics’, available at https://www.fda.gov/downloads/Drugs/Guidances/UCM358301.pdf (accessed 5 March 2018).
FDA–Food and Drug Administration (2015), ‘Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval, Guidance for Industry and Food and Drug Administration Staff’, available at https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm393994.pdf (accessed 5 March 2018).
FDA (2017), ‘Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff’ available at https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm513027.pdf (accessed 5 March 2018).
Feldman, J. D., Petersen, A. J., Karliner, L. S. and Tice, J. A. (2008), ‘Who is Responsible for Evaluating the Safety and Effectiveness of Medical Devices? The Role of Independent Technology Assessment’, Journal of General Internal Medicine, 23 (Suppl. 1): 5763.
Garber, A. M. (2001), ‘Evidence-Based Coverage Policy’, Health Affairs, 20 (5): 6282.
Gelijns, A. and Rosenberg, N. (1994), ‘The Dynamics of Technological Change in Medicine’, Health Affairs, 13 (3): 2846.
Gelijns, A. and Thier, S. (2002), ‘Medical Innovation and Institutional Interdependence: Rethinking University–Industry Connections’, Journal of the American Medical Association, 287 (1): 7277.
Gelijns, A., Zivin, J. G. and Nelson, R. R. (2001), ‘Uncertainty and Technological Change in Medicine’, Journal of Health Politics, Policy and Law, 26 (5): 913924.
Gurwitz, J. H., Sykora, K., Mamdani, M., Streiner, D. L., Garfinkel, S., Normand, S. T., Anderson, G. M. and Rochon, P. A. (2005), ‘Reader's guide to critical appraisal of cohort studies: 1. Role and Design’, British Medical Journal, 330 (7496): 895897.
Guyatt, G. H., Haynes, R. B., Jaeschke, R. Z., Green, L., Naylor, C. D., Wilson, M. C. and Richardson, W. S. for the Evidence-Based Medicine Working Group (2000), ‘Users’ Guides to the Medical Literature XXV. Evidence-Based Medicine: Principles for Applying the Users’ Guides to Patient Care’, Journal of the American Medical Association, 284 (10): 12901295.
Harper, D. (1996), Entrepreneurship and the Market Process. London: Routledge.
Health Affairs Health Policy Brief (2015a), The FDA's Sentinel Initiative, available at http://healthaffairs.org/healthpolicybriefs/brief_pdfs/healthpolicybrief_139.pdf (accessed 5 March 2018).
Health Affairs Health Policy Brief (2015b), Aligning FDA and CMS Review, available at https://www.healthaffairs.org/do/10.1377/hpb20150827.132391/full/healthpolicybrief_143.pdf (accessed 5 March 2018).
Hodgson, G. M. (2008), ‘An Institutional and Evolutionary Perspective on Health Economics’, Cambridge Journal of Economics, 32 (2): 235256.
Hoffman, S. and Podgurski, A. (2013), ‘Big Bad Data: Law, Public Health and Biomedical Databases’, Journal of Law, Medicine & Ethics, 41 (s1): 5660.
Hutchins, V. A., Samuels, M. B., and Lively, A. M. (2013), ‘Analyzing the Affordable Care Act: Essential Health Benefits and Implications for Oncology’, Journal of Oncology Practice, 9 (2): 7377.
Institute of Medicine (2000), Extending Medicare Reimbursement in Clinical Trials, Washington, DC: National Academies Press.
Institute of Medicine (2007), The Learning Healthcare System, Washington, DC: National Academies Press.
Institute of Medicine (2010), Clinical Data as the Basic Staple of Health Learning: Creating and Protecting a Public Good, Washington, DC: National Academies Press.
Institute of Medicine (2011), Digital Infrastructure for the Learning Health System: The Foundation for Continuous Improvement in Health and Health Care: Workshop Series Summary, Washington, DC: National Academies Press.
Junod, S. W. (2016), ‘FDA and Clinical Drug Trials: A Short History’, available at https://www.fda.gov/aboutfda/whatwedo/history/overviews/ucm304485.htm (accessed 5 March 2018).
Kravitz, R. L., Duan, N. and Braslow, J. (2004), ‘Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages’, Millbank Quarterly, 82 (4): 661687.
Lahr, J. G. (1995), What Is the Method to Their “Madness”? Experimental Treatment Exclusions in Health Insurance Policies’, Journal of Contemporary Health Law & Policy, 13 (2): 613636.
Lakdawalla, D. and Sood, N. (2012), ‘Incentives to Innovate’, in: Danzon, P. M. and Nicholson, S. (eds), The Oxford Handbook of Economics of the Biopharmaceutical Industry, Oxford: Oxford University Press, pp. 143166.
Loasby, B. (1999), Knowledge, Institutions and Evolution in Economics, London and New York: Routledge.
Loasby, B. J. (2001) ‘Time, Knowledge and Evolutionary Dynamics: Why Connections Matter’, Journal of Evolutionary Economics, 11 (4): 393412.
Mamdani, M., Sykora, K., Li, P., Streiner, D. L., Austin, P. C., Rochon, P. A. and Anderson, G. M. (2005), ‘Reader's Guide to Critical Appraisal of Cohort Studies: 2. Assessing the Potential for Confounding’, British Medical Journal, 330 (7497): 960962.
Martin, P. J., Davenport-Ennis, N., Petrelli, N. J., Stewart, F. M., Appelbaum, F. R. and Benson, A. III (2014) ‘Responsibility for Costs Associated With Clinical Trials’, Journal of Clinical Oncology, 32 (3): 33573360.
Mohr, P. E. and Tunis, S. R. (2010), ‘Access with Evidence Development: The US Experience’, Pharmacoeconomics, 28 (2): 153162.
Naci, H., Dias, S., and Ades, A. E. (2014), ‘Industry Sponsorship Bias in Research Findings: A Network Meta-Analysis of LDL Cholesterol Reduction in Randomised Trials of Statins’, British Medical Journal, 349: g5741. doi: 10.1136/bmj.g5741, available at www.bmj.com/content/bmj/349/bmj.g5741.full.pdf (accessed 5 March 2018).
National Academies of Science, Engineering, and Medicine (2017), Real-World Evidence Generation and Evaluation of Therapeutics: Proceedings of a Workshop. Washington, DC: National Academies Press. doi: 10.17226/24685.
National Research Council (2011), Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease, Washington, DC: National Academies Press.
Nelson, R. R., Buterbaugh, K., Perl, M. and Gelijns, A. (2011), ‘How Medical Know-How Progresses’, Research Policy, 40 (10): 13391344.
Neumann, P. J. (2004), ‘Why Don't Americans Use Cost-Effectiveness Analysis?American Journal of Managed Care, 10: 308312.
Neumann, P. J., Rosen, A. B., and Weinstein, M. C. (2005), ‘Medicare and Cost-Effectiveness Analysis’, New England Journal of Medicine 353: 15161522.
Neumann, P. J. and Chambers, J. D. (2012), ‘Medicare's Enduring Struggle to Define “Reasonable and Necessary” Care’, New England Journal of Medicine, 367: 17751777.
Normand, S. L., Sykora, K., Li, P., Mamdani, M., Rochon, P. A. and Anderson, G. M. (2005), ‘Reader's Guide to Critical Appraisal of Cohort Studies: 3. Analytical Strategies to Reduce Confounding’, British Medical Journal, 330 (7498): 10211023.
Raja, F. R. (2016), ‘Evidentiary Standards for Drug Approvals in the 21st Century Cures Act: A Continued Trend Towards Valuing Access Over Safety for Pharmaceutical Drugs’, North Carolina Journal of Law and Technology, 18: 409437.
Ramsey, S. D. (2015), ‘How State and Federal Policies As Well As Advances In Genome Science Contribute To The High Cost of Cancer Drugs’, Health Affairs 34 (4): 571575.
Sachs, R. R. (2016), ‘Your Weekly Reminder That FDA Approval and Insurance Coverage Are Often Linked’, Bill of Health blog (Harvard Law Petrie-Flom Center), available at http://blogs.harvard.edu/billofhealth/2016/11/30/your-weekly-reminder-that-fda-approval-and-insurance-coverage-are-often-linked/ (accessed 5 March 2018).
Sackett, D. L., Rosenberg, W. M. C., Muir Gray, J. A., Haynes, R. B. and Richardson, W. S. (1996), ‘Evidence Based Medicine: What It Is and What It Isn't’, British Medical Journal, 312: 7172.
Scotchmer, S. (2004), Innovation and Incentives, Cambridge, MA: MIT Press.
Sherman, R. E., Anderson, S. A., Dal Pan, G. J., Gray, G. W., Gross, T., Hunter, N. L., LaVange, L., Marinac-Dabic, D., Marks, P. W., Robb, M. A., Shuren, J. and Temple, R. (2016), ‘Real-World Evidence – What Is It and What Can It Tell Us?New England Journal of Medicine, 375 (23): 22932297.
Silverman, S. L. (2009), ‘From Randomized Controlled Trials to Observational Studies’, American Journal of Medicine, 122 (2): 114120.
Steinberg, E. P., Tunis, S. and Shapiro, D. (1995), ‘Insurance coverage for experimental technologies’, Health Affairs, 14 (4): 143158.
Sullivan, S. D., Watkins, J., Sweet, B. and Ramsey, S. D. (2009), ‘Health Technology Assessment in Health-Care Decisions in the United States’, Value in Health, 12 (Supp. 2): S39S44.
Temple, R. and Ellenberg, S. S. (2000), ‘Placebo-controlled Trials and Active Control Trials in the Evaluation of New Treatments. Part I: Ethical and Scientific Issues’, Annals of Internal Medicine, 133 (6): 455463.
Terry, N. P. (2014), ‘Big Data Proxies and Health Data Exceptionalism’, Health Matrix, 24: 65108.
Timmermans, S. and Mauck, A. (2005), ‘The Promises and Pitfalls of Evidence-based Medicine’, Health Affairs, 24 (1): 1828.
Towse, A. M. Drummon and Sorenson, C. (2012), Measuring Value: Pharmacoeconomics Theory and Practice. In: Danzon, P. M. and Nicholson, S. (eds), The Oxford Handbook of Economics of the Biopharmaceutical Industry, Oxford: Oxford University Press, pp. 394437.
Trosman, J. R., Van Bebber, S. L. and Phillips, K. A. (2011), ‘Health Technology Assessment and Private Payers’ Coverage of Personalized Medicine’, Journal of Oncology Practice, 7 (3S): 18s24s.
US Government Accountability Office (2006), Report to Requesters: Drug Safety, Improvements Needed in FDA's Postmarket Decision-making and Oversight Process.
Unger, J. M., Coltman, C. A., Crowley, J. J., Hutchins, L. F., Martino, S., Livingston, R. B., Macdonald, J. S., Blanke, C. D., Gandara, D. R., Crawford, E. D. and Albain, K. S. (2006), ‘Impact of the Year 2000 Medicare Policy Change on Older Patient Enrollment to Cancer Clinical Trials’. Journal of Clinical Oncology, 24 (1): 141144.
Wachter, R. (2015), The Digital Doctor: Hope, Hype, and Harm at the Dawn of Medicine's Computer Age, New York: McGraw Hill Education.
Weisbrod, B. A. (1991), ‘The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care, and Cost Containment’, Journal of Economic Literature, 29 (2): 523552.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Journal of Institutional Economics
  • ISSN: 1744-1374
  • EISSN: 1744-1382
  • URL: /core/journals/journal-of-institutional-economics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed